Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients

BACKGROUND: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis. This Phase 2a study tested efficacy (Hb response) and safety of roxadustat in anemic nondialysis-dependent chronic kidney disease (NDD-CKD) subjects. METHODS: NDD-CKD sub...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Nephrol Dial Transplant
Main Authors: Besarab, Anatole, Provenzano, Robert, Hertel, Joachim, Zabaneh, Raja, Klaus, Stephen J., Lee, Tyson, Leong, Robert, Hemmerich, Stefan, Yu, Kin-Hung Peony, Neff, Thomas B.
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2015
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4569392/
https://ncbi.nlm.nih.gov/pubmed/26238121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfv302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados